Last updated on January 2020

Safety and Tolerability of HepaStem in Patients With Cirrhotic and Pre-cirrhotic NASH Patients


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: NASH - Nonalcoholic Steatohepatitis
  • Age: Between 18 - 70 Years
  • Gender: Male or Female

Main Inclusion Criteria:

  • Able and willing to provide written informed consent and comply with the requirements of this study protocol
  • Age 18 to 70-years old, inclusive
  • Proven diagnosis of NASH based on histological evidence from biopsy performed within 6 months for F3 patients and within 2 years for F4 patients prior to Screening If no biopsy is available within these time windows, a biopsy should be performed at Screening NB: For F4 patients for whom the biopsy cannot confirm the diagnosis of NASH, any other causes of underlying liver diseases should be excluded

Main Exclusion Criteria:

  • Alcoholic liver disease or alcohol consumption exceeding the daily intake of 140g/w (two doses) for women and of 210g/w (three doses) for men
  • Other causes of liver disease including, but not limited to, alcoholic liver disease, active hepatitis B (HbsAg+), hepatitis C (PCR positive), autoimmune disorders, drug-induced hepatotoxicity, Wilson disease, hemochromatosis, and alpha-1-antitryspin deficiency based on medical history and/ or clinical and biological assessment
  • Recent recurrent or ongoing thrombotic or bleeding events within 3 months prior the screening
  • Patients considered at persistent risk of thrombosis or bleeding at the time of screening
  • Patients with high risk of Gastro intestinal bleeding at time of the screening.
  • Cerebrovascular, myocardial, or limb arterial thrombotic event within 12 months prior to the screening and/or not considered stabilized by the investigator
  • Bariatric surgery within 1 year prior to the screening
  • Coagulation disturbances defined as (Drolz et al. 2016, Nadim et al. 2016, Stravitz et al. 2018, Green et al. 2018): fibrinogen at < 80 mg/dL and/or platelets at < 40 x 10/mm3
  • Severe hepatic encephalopathy (defined by West Haven grade > 2)
  • Acute Decompensation of cirrhosis with Chronic Liver Failure Consortium Acute Decompensation (CLIF-C AD) score > 60
  • Acute on Chronic liver failure (ACLF) grade 1, 2 ,3
  • MELD score > 20
  • Child Pugh score C

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.